Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prostate cancer: Active surveillance not linked to higher mortality in Black men

Key clinical point: Black men with low-risk prostate cancer have an increased 10-year cumulative incidence of disease progression and definitive treatment, but not increased metastasis or prostate cancer-specific mortality compared with non-Hispanic White men.

Major finding: Black men vs non-Hispanic White men had higher 10-year cumulative incidence of disease progression (59.9% vs 48.3%; P less than .001) and receipt of definitive treatment (54.8% vs 41.4%; P less than .001). Black men vs non-Hispanic White men did not show significant differences in metastasis (1.5% vs 1.4%; P = .49), prostate cancer-specific mortality (1.1% vs 1.0%; P = .82) and all-cause mortality (22.4% vs 23.5%; P = .09).

Study details: The study included 2280 Black and 6446 non-Hispanic White men diagnosed with low-risk prostate cancer and managed with active surveillance.

Disclosures: The study was supported by grants from the National Institutes of Health (NIH) and the Department of Defense. T Courtney and BS Rose reported receiving grants from the NIH and the Department of Defense, respectively. JK Parsons, JD Murphy and CJ Kane reported relationships with various companies. The remaining authors declared no conflicts of interest.


Deka R et al. JAMA. 2020 Nov 3. doi: 10.1001/jama.2020.17020.